Choong Ang Vaccine Laboratory Co. Ltd
Choong Ang Vaccine Laboratory Co., Ltd. engages in the research, development, manufacturing, and sale of animal vaccines in South Korea, Asia, Africa, and the United States. It offers swine, poultry, cattle, canine, feline, wild boar, and raccoon vaccines under the SuiShot, PoulShot, BoviShot, CaniShot, and FeliShot brands. The company was founded in 1968 and is headquartered in Daejeon, South Ko… Read more
Choong Ang Vaccine Laboratory Co. Ltd (072020) - Total Assets
Latest total assets as of September 2025: ₩122.80 Billion KRW
Based on the latest financial reports, Choong Ang Vaccine Laboratory Co. Ltd (072020) holds total assets worth ₩122.80 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Choong Ang Vaccine Laboratory Co. Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Choong Ang Vaccine Laboratory Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Choong Ang Vaccine Laboratory Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Choong Ang Vaccine Laboratory Co. Ltd's total assets of ₩122.80 Billion consist of 42.6% current assets and 57.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩13.46 Billion | 0.0% |
| Accounts Receivable | ₩5.04 Billion | 4.1% |
| Inventory | ₩17.69 Billion | 14.4% |
| Property, Plant & Equipment | ₩64.42 Billion | 52.3% |
| Intangible Assets | ₩1.06 Billion | 0.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Choong Ang Vaccine Laboratory Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Choong Ang Vaccine Laboratory Co. Ltd's current assets represent 42.6% of total assets in 2024, a decrease from 44.1% in 2014.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 12.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 52.3% of total assets.
Choong Ang Vaccine Laboratory Co. Ltd Competitors by Total Assets
Key competitors of Choong Ang Vaccine Laboratory Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Choong Ang Vaccine Laboratory Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Choong Ang Vaccine Laboratory Co. Ltd generates 0.37x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Choong Ang Vaccine Laboratory Co. Ltd generates $5.56 in net profit.
Choong Ang Vaccine Laboratory Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.61 | 4.97 | 3.40 |
| Quick Ratio | 2.74 | 3.20 | 2.12 |
| Cash Ratio | 0.00 | 1.05 | 0.00 |
| Working Capital | ₩41.30 Billion | ₩ 40.75 Billion | ₩ 29.89 Billion |
Choong Ang Vaccine Laboratory Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Choong Ang Vaccine Laboratory Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.86 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.1% |
| Total Assets | ₩123.28 Billion |
| Market Capitalization | $40.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Choong Ang Vaccine Laboratory Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Choong Ang Vaccine Laboratory Co. Ltd's assets grew by 3.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Choong Ang Vaccine Laboratory Co. Ltd (2014–2024)
The table below shows the annual total assets of Choong Ang Vaccine Laboratory Co. Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩123.28 Billion | +3.08% |
| 2023-12-31 | ₩119.59 Billion | +4.12% |
| 2022-12-31 | ₩114.86 Billion | +1.69% |
| 2021-12-31 | ₩112.95 Billion | +7.59% |
| 2020-12-31 | ₩104.98 Billion | +8.71% |
| 2019-12-31 | ₩96.57 Billion | -0.18% |
| 2018-12-31 | ₩96.74 Billion | +18.52% |
| 2017-12-31 | ₩81.62 Billion | +10.99% |
| 2016-12-31 | ₩73.54 Billion | +18.42% |
| 2015-12-31 | ₩62.10 Billion | +2.48% |
| 2014-12-31 | ₩60.60 Billion | -- |